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Abstract 
Manganese ortho tetrakis(N-n-butoxyethylpyridinium-2-yl)porphyrin, MnTnBuOE-2-PyP
5+
, is a third-
generation redox-active compound currently undergoing preclinical exploration. This work is intended to 
complement the already extensive research of its chemical and biological properties by a simple 
electrochemical study. The thermodynamic parameters related to the Mn(IV) porphyrin species of 
MnTnBuOE-2-PyP
5+
 determined in this work support its observed reactivity as an efficient scavenger of 
peroxynitrite. The corresponding driving forces for the possible single-electron or two-electron reductions of 
ONOO
-
 have been estimated as well. 
Keywords 




Therapeutic potential of metalloporphyrin-based mimics of superoxide dismutase (SOD) enzyme has 
been well documented [1-5]. Briefly, a true SOD mimic should be able to dismutate superoxide (i.e. oxidize 
or reduce O2
• -) at a catalytic rate, kcat(O2
• -), higher than the rate of O2
• - self-dismutation (5 × 105 M-1s-1 at 
pH = 7). The formal reduction potential of the SOD mimic should be optimally midway between the single-
electron formal reduction potentials for oxygen (E0’ = – 0.16 V vs. NHE) and superoxide (E0’ = + 0.89 V vs. 
NHE) [6-7]. Over the last 15 years, a rational approach to the design of potential SOD mimics led to the 
development of several manganese porphyrin complexes (MnPs) with unique electronic properties and 
high reactivity towards O2
• -, but also other reactive species such as peroxynitrite, ONOO- [2-5]. Indeed, a 
structure-activity relationship (half-wave reduction potential, E1/2, vs. log kcat(O2
• -)) has been developed and 
found to be valid for any other class of SOD mimics as well [1]. 
Recent efforts have been directed towards increasing the bioavailability and reducing the toxicity of 
MnPs. The original structure of a potent first-generation SOD mimic, manganese ortho tetrakis(N-
ethylpyridinium-2-yl)porphyrin (MnTE-2-PyP5+) was modified via lengthening the alkyl chains of pyridyl 
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substituents, yielding the more lipophilic compound, the manganese ortho tetrakis(N-n-hexylpyridinium-2-
yl)porphyrin (MnTnHex-2-PyP5+) [8]. This second-generation compound showed much higher brain and 
mitochondrial distribution than MnTE-2-PyP5+, but was also found to be toxic at higher concentrations and 
could have a potentially limited use [9-10]. The third-generation compound, manganese ortho tetrakis(N-n-
butoxyethylpyridinium-2-yl)porphyrin (MnTnBuOE-2-PyP5+), was designed via introduction of oxygen atoms 
into the alkyl chains on the pyridyl substituents. This compound preserved high redox-activity and 
lipophilicity but exhibited significantly reduced toxicity relative to MnTnHex-2-PyP5+ [11]. 
Comparison of MnTE-2-PyP5+ and MnTnBuOE-2-PyP5+ with regards to their redox properties (E1/2 for 
MnIIIP/MnIIP redox couple), reactivities towards superoxide, log kcat(O2
• -), and peroxynitrite, log kred(ONOO
-), 
as well as lipophilicities (distribution between n-octanol and water, log POW) is given in Table 1. 
 





. Data are taken from references [3-5,11-16] ; 
a
 at 25 °C; 
b








E1/2 (mV vs. NHE) + 228 + 277 
log kcat (O2
•-) a 7.76 7.83 
log kred (ONOO
-) b 7.53 7.54 
log POW -7.79 -4.10 
 
Comprehensive studies on bioavailability of these compounds have been performed recently as well [17-
19], in order to gain further insight into the biodistribution of MnPs, but also provide guidelines for proper 
dosing regimens. After assessing preliminary efficacy and toxicity data, the porphyrins were administered 
to mice intraperitoneally (ip) or intravenously (iv) at following doses: 10 mg/kg of MnTE-2-PyP5+ (ip) and 2 
mg/kg of MnTnBuOE-2-PyP5+ (iv). Drug levels in plasma and different organs were followed during at least 
24 hours after a single dose, thus allowing the calculation of relevant pharmacokinetic (PK) parameters via 
non-compartmental analysis of PK curves. 
These studies showed the highest MnP bioavailability in liver (maximum concentration, Cmax, values of 
8.1 and 13.1 µmol per L of tissue homogenate for MnTE-2-PyP5+ and MnTnBuOE-2-PyP5+, respectively) and 
kidney, followed by spleen, lung and heart, whereas lower levels were found in plasma and lowest in the 
brain. Remarkably, MnTnBuOE-2-PyP5+ has 8-fold higher brain bioavailability (expressed as the area under 
PK curve, AUC, divided by dose) than the less lipophilic MnTE-2-PyP5+ (Figure 1), which may be highly 
significant for its potential application as a brain tumor radio- and chemo-therapeutic [20-21].  
Additionally, it has been shown that kcat(O2
• –) parallels the ability of MnPs to reduce ONOO- [4-5,14], due 
to the same thermodynamic and kinetic factors facilitating the reaction of electron-deficient cationic MnPs 
with electron-donating anionic species, such as O2
• – and ONOO- [3-5,22]. Specifically, the removal of ONOO- 
can occur either through its binding to the Mn(III) site followed by its one-electron reduction to NO2
• radical 
(coupled to the oxidation of MnIIIP to MnIVP), or the two-electron reduction of ONOO- by the MnIIP species 
(coupled to the oxidation of MnIIP to MnIVP). The latter reaction produces less toxic nitrite, NO2
-, and might 
in fact be dominant in vivo due to (i) the abundance of cellular reductants keeping MnPs in Mn(II) state 
[1,13,23-25] and (ii) a higher driving force making it thermodynamically favorable [26]. 
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demonstrated as 24-hour dose-adjusted AUC values: raw AUC values have been divided by dose (10 mg/kg for 
MnTE-2-PyP
5+
 and 2 mg/kg for MnTnBuOE-2-PyP
5+
). The values for MnTE-2-PyP
5+
 determined via iv route are 
taken as 100 % availability (plasma bioavailability via ip route was found to be approximately 84% of 
bioavailability via iv route for MnTE-2-PyP
5+
) [18]. MnPs’ charges have been omitted from the plot for simplicity. 
 
MnTnBuOE-2-PyP5+ represents the latest generation of redox-active compounds and is currently 
undergoing preclinical exploration. This work is intended to complement the already extensive research of 
its chemical and biological properties by a simple electrochemical study. 
Experimental  
The investigated metalloporphyrin, MnIIITnBuOE-2-PyPCl5 was synthesized according to the published 
procedure [11]. Stock solution was prepared by dissolution of purified and characterized solid (known molar 
absorbance coefficient, ε456 (MnTnBuOE-2-PyP
5+) = 1.78 × 105 M-1 cm-1) [11]. Cyclic voltammetry of buffered 
and deaerated solutions was performed as reported in a previous study [26]. All potentials are reported vs. 
the normal hydrogen electrode (NHE), using the known potential of MnTE-2-PyP5+, E1/2 = + 228 mV vs. NHE 
at pH 7.8, as a reference [11,27-28]. 
Results and Discussion 
Cyclic voltammograms of the aqueous solutions of MnIIIPs can show two distinct electron transfers: only 
one current peak pair attributed to the MnIIIP/MnIIP redox couple is observed in a neutral or mildly basic 
medium (pH = 7.8, Figure 2), whereas in the more basic medium an additional current peak pair attributed 
to the MnIVP/MnIIIP redox couple appears at more positive potentials (pH = 11, Figure 2). The cathodic and 
anodic current peak potentials, Epc and Epa, of both redox couples shift toward more negative values upon 
the increased pH of the solution. The cathodic-anodic peak separation, ΔEp = |Epc - Epa| for both redox 
processes is larger than 59 mV even at the scan rate of 0.02 V s-1, indicating quasi-reversible electron 
transfer processes. 
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Figure 2. Comparison of cyclic voltammograms of 0.5 mM aqueous solutions of MnTnBuOE-2-PyP
5+
 at 
pH=7.8 and pH = 11, ν = 0.02 V s
-1
, [NaCl] = 0.1 M,  = 25 °C. Similar behavior has been reported 









P couples (left cycle). 
These results are in agreement with the previously established scheme of behavior of MnPs in aqueous 
solutions [26,30]. At pH = 7.8 only a single-electron reduction of MnIIIP can be observed, shown by eq. (1), 
whereas at pH = 11 the single-electron reduction of MnIVP is accompanied by a simultaneous dissociation of 
two protons, according to eq. (2). The latter electron transfer cannot be observed in a neutral medium due 
to a formal potential more positive than that of water (E0’(O2(g),H
+(aq.)/H2O(l)) = 816 mV vs. SHE at pH = 7) 
[30-31]. 
           III 5 II 42 2 22H O Mn TnBuOE 2 PyP e H O Mn TnBuOE 2 PyP H O  (1) 
             IV 4 III 52 2 2O H O Mn TnBuOE 2 PyP  2H  e H O Mn TnBuOE 2 PyP  (2) 
 















. Values for MnTE-2-PyP
5+
 are taken from reference [26] and adjusted to 























E1/2 (mV vs. NHE) 
pH = 7.8 pH = 11 
MnIIIP/MnIIP MnIIIP/MnIIP MnIVP/MnIIIP MnIVP/MnIIP 
MnTnBuOE-2-PyP5+ + 277 + 235 + 624 + 430 
MnTE-2-PyP5+ + 228 + 208 + 592 + 400 
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As shown previously [11], the E1/2 of Mn
IIIP/MnIIP redox couple of MnTnBuOE-2-PyP5+ is close to the 
value of the Mn SOD enzyme itself, accounting for its high reactivity towards O2
•– (even higher than that of 
MnTE-2-PyP5+, Table 1). Thermodynamic parameters related to the MnIVP species of MnTnBuOE-2-PyP5+ 
determined in this work (Table 2) support its observed reactivity as an efficient scavenger of peroxynitrite. 
Estimating the shift of the E1/2 (Mn
IVP/MnIIIP) value for +118 mV per unit decrease of pH from pH = 11, 
yields the values of E1/2 (Mn
IVP/MnIIIP) = + 1049 mV vs. NHE at the physiological pH, according to eq. (2). The 
E1/2 (Mn




IVP/MnIIIP)]/2 = + 663 mV vs. NHE. Finally, the driving forces for the single-electron and two-electron 
reduction of ONOO-, EMF (1e-) = 551 mV and EMF (2e-) = 637 mV, can then be calculated as EMF = Ec - Ea, 
where the values of Ec are the formal potentials E
0’(ONOO-/NO2
•) = 1.6 V and E0’(ONOO-/NO2
-) = 1.3 V [32], 





Considerable interest in the impact of oxidative stress on cellular function prompted an intensive search 
for natural and synthetic antioxidants. High bioavailability of MnTnBuOE-2-PyP5+, coupled with its 
exceptional physicochemical properties as a redox-active ROS/RNS scavenger, makes it a promising 
candidate in the ongoing cancer and radioprotection preclinical studies. 
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